Chau, Ian http://orcid.org/0000-0003-0286-8703
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Poon, Ronnie
Pastorelli, Davide
Blanc, Jean-Frédéric
Kudo, Masatoshi
Pfiffer, Tulio
Hatano, Etsuro
Chung, Hyun Cheol
Kopeckova, Katerina
Phelip, Jean-Marc
Brandi, Giovanni
Ohkawa, Shinichi
Li, Chung-Pin
Okusaka, Takuji
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew X.
Article History
Received: 25 October 2017
Revised: 4 April 2018
Accepted: 11 April 2018
First Online: 29 May 2018
Ethical Approval
: Each centre’s institutional review board or ethics committee approved the study. The trial followed the principles of the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation. All patients provided written informed consent.
: I.C. reports advisory board roles at Sanofi Oncology, Eli Lilly and Company, Bristol Meyers Squibb, MSD, Bayer, Roche, Five Prime Therapeutics; honoraria from Taiho, Pfizer, Amgen, Eli-Lilly, Gilead Science; research funding from Janssen-Cilag, Sanofi Oncology, Merck-Serono, Novartis. J.O.P. reports receiving clinical research grants, honoraria from Celgene and research grant from AstraZeneca. He reports a role on the advisory board for Celgene. J.-F.B. reports payments from Lilly Oncology, Bayer SP, BMS and Novartis outside the submitted work. M.K. received research grants from Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, Abbvie, Medico’s Hirata, Astellas Pharma and Bristol-Myers Squibb; lecture fees from Bayer, Eisai, MSD, Ajinomoto, Kowa and Taiho; and consulting fees from Kowa, MSD, BMS, Bayer, Chugai, Taiho and Eisai. H.C.C. is a consultant for Eli Lilly and Company, MSD, Merck-Serono, Taiho, BMS, Celltrion, he has received research grants from Eli Lilly and Company, GSK and MSD. J.-M.P. reports receiving research grants from Roche and Merck and payments from Eli Lilly and Company, Bayer, Sanofi, Roche and Merck. T.O. reports research grants, advisory role and honoraria from Eli Lilly, during the conduct of the study; he also reports research grants advisory role and/or honoraria from Novartis Pharma K.K., Kowa K.K., Takeda Bio Development Center Limited, Nippon Boehringer Ingelheim Co., Ltd., Dainippon Simitomo Pharma Co., Ltd., Pfizer Jana Inc, Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Yakuruto Honsha Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd, AstraZeneca K.K., Merck Serono Co., Ltd., OncoTherapy Science Inc., Kyowa Hakko Kirin Co., Ltd., Shizuoka Industry, Baxter, Nano Carrier Co., Ltd., Zeria Pharmaceutical Co., Ltd., Glaxo Smith Kline K.K., Nobelpharma Co., Ltd., burisutoru, Nipponchemofa, EA Pharma Co., Ltd., FUJIFILM RI Pharma Co., Ltd., Astellas Pharma Inc., Nippon Kayaku Co., Ltd., Daiichi Sankyo Co., Ltd., J-CRSU CO., LTD., outside the submitted work. P.A. and Y.H. are employees of Eli Lilly and Company and own stock from Eli Lilly and Company. A.X.Z. reports that his institution received research support from Eli Lilly and Company. The other authors declare no competing interests.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0).